Karim Fizazi v. Bertrand Tombal on 'Hormone-naive metastatic prostate cancer patients should get chemotherapy and ADT as a standard of care' versus 'ADT and AR pathway-targeted agents still have a role in these patients’ - STOP 6

Debate between Karim Fizazi and Bertrand Tombal on 'Hormone-naive metastatic prostate cancer patients should get chemotherapy and ADT as a standard of care' versus 'ADT and AR pathway-targeted agents still have a role in these patients’ (STOP 6)

Biographies:
Karim Fizazi, MD

Bertrand Tombal, MD, PhD, us professor and Chairman, Service d'Urologie, Cliniques universitaires Saint Luc, Université catholique de Louvain, Brussels, Belgium Professor Bertrand Tombal is Chairman of the Division of Urology and Associated Professor of Physiology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint‐Luc in Brussels, Belgium. His primary clinical interest is the treatment of the advanced stages of prostate cancer, and particularly hormonal treatment and the development of new biological agents and he is Head of the Uro‐oncology Division at the Université catholique de Louvain where he is currently coordinating several clinical trials in this research area.